Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 2/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 8/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.42 |
| ▸ | TUBB | P07437 | 5/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903386 | 1.00 | CYP1A1 (0.43) | CYP1A1CYP1B1CYP1A2ALDH1A1TP53 | |
| SCHEMBL6900692 | 0.88 | TUBB1 (0.50) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| SCHEMBL6900688 | 0.88 | TUBB1 (0.50) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| SCHEMBL6753698 | 0.88 | CYP1A1 (0.52) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| SCHEMBL22455879 | 0.88 | CYP1A1 (0.52) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| SCHEMBL6753697 | 0.88 | CYP1A1 (0.52) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| SCHEMBL6905566 | 0.86 | CYP1A1 (0.50) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| SCHEMBL6905562 | 0.86 | CYP1A1 (0.50) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| SCHEMBL6905296 | 0.84 | CYP1A1 (0.43) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A | |
| SCHEMBL6905294 | 0.84 | CYP1A1 (0.43) | CYP1A1CYP1B1CYP1A2TUBB1TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8198302-B2 | Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1 | OXIGENE, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | MATEON THERAPEUTICS, INC. | 2004-12-02 | — | — | US | disclosed |
| US-6759480-B1 | SUCH AS ETHYLENE-2-ETHYLHEXYL ACRYLATE COPOLYMER; IMPACT STRENGTH | ATOFINA (FR) | 2004-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242696-A1 | Compositions and methods with enhanced therapeutic activity | NQO1, MKI67, COMT | CYP1A1 809/4885CYP1B1 1230/4885CYP1A2 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.